Summary
AmerisourceBergen, Inc. (COR) reported strong revenue growth in its 2002 10-K filing, primarily driven by the significant merger with Bergen Brunswig Corporation completed in August 2001. The company operates in two main segments: Pharmaceutical Distribution and PharMerica (institutional pharmacy services). The Pharmaceutical Distribution segment is the larger contributor, benefiting from industry tailwinds such as an aging population and increased use of outpatient drug therapies. Management highlighted a strategic focus on continued growth in existing markets and expansion through value-added healthcare solutions for both customers and suppliers. While revenue saw a substantial increase, the company also detailed ongoing integration efforts and associated costs following the merger. Key initiatives include streamlining its distribution network and eliminating duplicate administrative functions to achieve significant annual synergies. Several acquisitions were also completed or announced, indicating a commitment to inorganic growth and expanding service offerings. The company faced competitive pressures impacting gross profit margins, but managed operating expenses effectively, leading to improved operating income. Investors should note the company's stated intention to continue paying quarterly cash dividends and its significant debt position resulting from the merger, which is being managed through various credit facilities and note issuances.
Key Highlights
- 1Significant revenue growth, increasing 154% to $40.2 billion, largely attributed to the merger with Bergen Brunswig Corporation completed in August 2001.
- 2The company operates two primary segments: Pharmaceutical Distribution (the larger segment) and PharMerica (institutional pharmacy services).
- 3Strategic focus on expanding healthcare solutions for customers and suppliers, complemented by several recent and pending acquisitions (AutoMed, Bridge Medical, US Bioservices).
- 4Ongoing merger integration efforts are underway, targeting approximately $150 million in annual synergies through distribution network consolidation and administrative cost reductions.
- 5Gross profit margin in the Pharmaceutical Distribution segment faced downward pressure due to competitive pricing and a shift in customer mix, though this was partially offset by efficiency gains.
- 6The company initiated quarterly cash dividends in fiscal year 2001 and anticipates continuing them, subject to board discretion.
- 7Significant debt was incurred in relation to the merger, with management actively managing its debt structure through various credit facilities and note issuances.